Related Experiment Videos
beta-catenin expression and mutational analysis in renal cell carcinomas
1Department of Pathology, College of Medicine, Korea University, Gojan-Dong, Ansan, Korea. apysk@yahoo.com
Pathology International
|September 30, 2000
Summary
Beta-catenin mutations are rare in renal cell carcinoma (RCC). However, cytoplasmic beta-catenin accumulation occurs in conventional RCC, suggesting its signaling pathway activation contributes to this cancer type.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Beta-catenin is a key transcriptional activator in the Wingless-Wnt signaling pathway.
- This pathway regulates cell proliferation and apoptosis.
- Aberrant Wnt signaling, due to APC or beta-catenin mutations, is implicated in various cancers.
Purpose of the Study:
- To investigate the role of beta-catenin gene mutations and protein expression in renal cell carcinogenesis.
- To determine if abnormal beta-catenin is linked to different subtypes of renal cell carcinoma (RCC).
Main Methods:
- Analysis of 52 renal cell carcinomas (RCC) using immunohistochemistry, PCR-SSCP, and DNA sequencing.
- Examined beta-catenin protein localization (membranous, cytoplasmic, nuclear) and mutations in exon 3.
Main Results:
- No nuclear beta-catenin staining was observed in any RCC or normal kidney samples.
- Cytoplasmic accumulation of beta-catenin was found in 22.7% of conventional (clear cell) RCC, but not in papillary or chromophobe types.
- A single missense mutation in beta-catenin exon 3 was identified in one conventional RCC case.
Conclusions:
- Beta-catenin mutations are infrequent in renal cell carcinoma.
- Cytoplasmic accumulation of beta-catenin protein is specific to conventional (clear cell) RCC.
- Wnt signaling pathway activation may contribute to the development of conventional RCC.